<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8A80CC50-1F16-42D3-ACB0-39D79F5CBB85"><gtr:id>8A80CC50-1F16-42D3-ACB0-39D79F5CBB85</gtr:id><gtr:name>ProteinLogic Limited</gtr:name><gtr:address><gtr:line1>Shakespeare House
42 Newmarket Street</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB5 8EP</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A80CC50-1F16-42D3-ACB0-39D79F5CBB85" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8A80CC50-1F16-42D3-ACB0-39D79F5CBB85</gtr:id><gtr:name>ProteinLogic Limited</gtr:name><gtr:address><gtr:line1>Shakespeare House
42 Newmarket Street</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB5 8EP</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>118064.0</gtr:offerGrant><gtr:projectCost>157419.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7C4A7A63-AFA9-4281-90D0-E43F1E6A6103" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>7C4A7A63-AFA9-4281-90D0-E43F1E6A6103</gtr:id><gtr:name>The Foundation for Liver Research</gtr:name><gtr:address><gtr:line1>HAROLD SAMUEL HOUSE, 69-75 , CHENIES MEWS</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1E 6HX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>9500.0</gtr:offerGrant><gtr:projectCost>9500.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/987D4FEC-5643-4D03-AFDC-9C125224B671"><gtr:id>987D4FEC-5643-4D03-AFDC-9C125224B671</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Rodgers</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131612"><gtr:id>800C1CBF-6338-4FAA-9BCA-9BC9B5DBA94D</gtr:id><gtr:title>Technical and Commercial Feasibility of a blood test for prediction of response to interferon treatment in Chronic Hepatitis B patients</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131612</gtr:grantReference><gtr:abstractText>Hepatitis B is the most common chronic viral disease in the world with over 350 million chronic carriers. Taking into account the recent migration patterns it is estimated that that there are now more than 300,000 people in the UK with HBV infection and, of these, 78,000 have Chronic Hepatitis B infection. NICE recommends that interferon be used as the first line treatment for Chronic Hepatitis B. However interferon treatment has a long duration (6-12 months), considerable side effects including fever, neurological and gastrointestinal disorders and whilst it can be very effective only 30% of patients respond to treatment. ProteinLogic has identified biomarkers that can be used as a simple diagnostic blood test for the prediction of response to treatment with interferon in patients with chronic HBV infection before start of treatment, therefore providing significant benefits to patients and saving healthcare costs in the UK and worldwide.</gtr:abstractText><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>127564</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131612</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>